Hanmi Science Co., Ltd.

KSE 008930.KS

Hanmi Science Co., Ltd. Return on Capital Employed (ROCE) for the year ending December 31, 2023: 8.81%

Hanmi Science Co., Ltd. Return on Capital Employed (ROCE) is 8.81% for the year ending December 31, 2023, a 79.80% change year over year. Return on capital employed assesses profitability against invested capital; higher ROCE signals efficient capital use.
  • Hanmi Science Co., Ltd. Return on Capital Employed (ROCE) for the year ending December 31, 2022 was 4.90%, a -29.82% change year over year.
  • Hanmi Science Co., Ltd. Return on Capital Employed (ROCE) for the year ending December 31, 2021 was 6.99%, a 102.02% change year over year.
  • Hanmi Science Co., Ltd. Return on Capital Employed (ROCE) for the year ending December 31, 2020 was 3.46%, a 54.06% change year over year.
  • Hanmi Science Co., Ltd. Return on Capital Employed (ROCE) for the year ending December 31, 2019 was 2.24%, a 225.04% change year over year.
Key data
Date Return on Capital Employed (ROCE) Interest Coverage Ratio Debt to Equity Ratio Return on Common Equity
Market news
KSE: 008930.KS

Hanmi Science Co., Ltd.

CEO Mr. Jong-Hoon Lim
IPO Date Sept. 29, 2005
Location South Korea
Headquarters 14, Wiryeseong-daero
Employees 402
Sector Health Care
Industries
Pharmaceuticals Biotechnology
Description

Hanmi Science Co., Ltd., through its subsidiaries, manufactures and sells pharmaceutical products in Korea and internationally. It develops drugs in the areas of diabetes and anti-cancer. The company also offers drug substances, general medicines, health functional foods, and nutrition and health products and services. In addition, it operates an online pharmacy; and offers pharmaceutical management automation systems. The company was formerly known as Hanmi Holdings Co., Ltd. and changed its name to Hanmi Science Co., Ltd. in March 2012. Hanmi Science Co., Ltd. was founded in 1973 and is based in Seoul, South Korea.

StockViz Staff

January 15, 2025

Any question? Send us an email